Home | About Us | Investors | Therapies | Platform | Leadership | Lactose Intolerance | News | Contact Us | Privacy Policy | Terms & Conditions | Site Map
© Copyright 2019 Ritter Pharmaceuticals. All Rights Reserved
Connect with us 
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Our lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 has been studied in Phase 2 trials and is now in Phase 3 clinical development. We are further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.
- Ritter’s medical advisory board represents the world’s experts in lactose intolerance
- Worldwide more than 1 billion people suffer from lactose intolerance
- Read more about lactose intolerance
- A breakthrough treatment aiming to eradicate symptoms of lactose intolerance
- Potential to become the first FDA-approved treatment for lactose intolerance
- Studied in Phase 2 trials
Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019LOS ANGELES (May, 14 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the… »- Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in PatientsTop-line Data Readout on Target for early Q4 2019 LOS ANGELES (May 7, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq:… »
